Real-life clinical benefit of oral metronomic cyclophosphamide administration in elderly and heavily pretreated epithelial ovarian cancer patients.

Daniela AttianeseRoberta MassobrioMargherita GiorgiMichela VillaLuca FusoEnrico BadellinoMarco BelleroAnnamaria Ferrero

Published in: Archives of gynecology and obstetrics (2024)

OMC is a feasible therapeutic option for recurrent ovarian cancer, providing satisfying clinical responses with a good toxicity profile, even in elderly and heavily pretreated patients with a suboptimal performance status.

Keyphrases

middle aged
low dose
oxidative stress
high dose
community dwelling